Aurora cannabis announces fiscal 2022 fourth quarter and full year results

Remains #1 canadian lp in high margin global medical cannabis revenues; international medical cannabis net revenue increased 35.4% from q4 2021 and 70.3% from fiscal 2021 reiterates adjusted ebitda profitability run rate by december 31, 2022 reaffirms $150 to $170 million in annualized cost savings by december 31, 2022 strengthens balance sheet through accretive debt reduction totaling $155.3 million in q4 2022 completed profitable acquisition of thrive cannabis and majority investment in bevo farms edmonton, ab , sept. 20, 2022 /prnewswire/ - aurora cannabis inc. (the "company" or "aurora") (nasdaq: acb) (tsx: acb), the canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the fourth quarter and fiscal year ended june 30, 2022.
ACB Ratings Summary
ACB Quant Ranking